These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 34928306)

  • 1. Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials.
    Ashina M; Goadsby PJ; Dodick DW; Tepper SJ; Xue F; Zhang F; Brennan F; Paiva da Silva Lima G
    JAMA Neurol; 2022 Feb; 79(2):159-168. PubMed ID: 34928306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
    Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Controlled Trial of Erenumab for Episodic Migraine.
    Goadsby PJ; Reuter U; Hallström Y; Broessner G; Bonner JH; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA
    N Engl J Med; 2017 Nov; 377(22):2123-2132. PubMed ID: 29171821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial.
    Pozo-Rosich P; Dolezil D; Paemeleire K; Stepien A; Stude P; Snellman J; Arkuszewski M; Stites T; Ritter S; Lopez Lopez C; Maca J; Ferraris M; Gil-Gouveia R
    JAMA Neurol; 2024 May; 81(5):461-470. PubMed ID: 38526461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
    Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
    Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular safety of erenumab for migraine prevention.
    Kudrow D; Pascual J; Winner PK; Dodick DW; Tepper SJ; Reuter U; Hong F; Klatt J; Zhang F; Cheng S; Picard H; Eisele O; Wang J; Latham JN; Mikol DD
    Neurology; 2020 Feb; 94(5):e497-e510. PubMed ID: 31852816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study.
    Tepper SJ; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein SD; Winner P; Zhang F; Cheng S; Mikol DD
    Cephalalgia; 2020 May; 40(6):543-553. PubMed ID: 32216456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.
    Dodick DW; Ashina M; Brandes JL; Kudrow D; Lanteri-Minet M; Osipova V; Palmer K; Picard H; Mikol DD; Lenz RA
    Cephalalgia; 2018 May; 38(6):1026-1037. PubMed ID: 29471679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of erenumab in women with a history of menstrual migraine.
    Pavlovic JM; Paemeleire K; Göbel H; Bonner J; Rapoport A; Kagan R; Zhang F; Picard H; Mikol DD
    J Headache Pain; 2020 Aug; 21(1):95. PubMed ID: 32746775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
    Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
    Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Lenz R; Wang Y; Cheng S; Hirama T; Mikol DD
    Headache; 2019 Nov; 59(10):1731-1742. PubMed ID: 31612482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials.
    Lampl C; Kraus V; Lehner K; Loop B; Chehrenama M; Maczynska Z; Ritter S; Klatt J; Snellman J
    J Headache Pain; 2022 Aug; 23(1):104. PubMed ID: 35978286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions.
    Zhou Y; Zhang F; Starcevic Manning M; Hu Z; Hsu CP; Chen PW; Peng C; Loop B; Mytych DT; Paiva da Silva Lima G
    Cephalalgia; 2022 Jul; 42(8):749-760. PubMed ID: 35272533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions.
    Ashina M; Kudrow D; Reuter U; Dolezil D; Silberstein S; Tepper SJ; Xue F; Picard H; Zhang F; Wang A; Zhou Y; Hong F; Klatt J; Mikol DD
    Cephalalgia; 2019 Dec; 39(14):1798-1808. PubMed ID: 31707815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response.
    Broessner G; Reuter U; Bonner JH; Dodick DW; Hallström Y; Picard H; Zhang F; Lenz RA; Klatt J; Mikol DD
    Headache; 2020 Oct; 60(9):2026-2040. PubMed ID: 32851644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
    Tepper SJ; Ashina M; Reuter U; Hallström Y; Broessner G; Bonner JH; Picard H; Cheng S; Chou DE; Zhang F; Klatt J; Mikol DD
    J Headache Pain; 2021 Jul; 22(1):81. PubMed ID: 34301173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study.
    Wang SJ; Roxas AA; Saravia B; Kim BK; Chowdhury D; Riachi N; Tai MS; Tanprawate S; Ngoc TT; Zhao YJ; Mikol DD; Pandhi S; Wen S; Mondal S; Tenenbaum N; Hours-Zesiger P
    Cephalalgia; 2021 Nov; 41(13):1285-1297. PubMed ID: 34171973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
    Takeshima T; Sakai F; Hirata K; Imai N; Matsumori Y; Yoshida R; Peng C; Cheng S; Mikol DD
    Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.
    Goadsby PJ; Paemeleire K; Broessner G; Brandes J; Klatt J; Zhang F; Picard H; Lenz R; Mikol DD
    Cephalalgia; 2019 Jun; 39(7):817-826. PubMed ID: 30982348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study.
    Reuter U; Goadsby PJ; Ferrari MD; Da Silva Lima GP; Mondal S; Kalim J; Hasan F; Wen S; Arkuszewski M; Pandhi S; Stites T; Lanteri-Minet M
    Neurology; 2024 May; 102(10):e209349. PubMed ID: 38669638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.